Owen Nishikawa, MD
Family Medicine · Honolulu, HINPI 1053471797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 367 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,451 and has fallen 51.2% since, to $708 in 2025. Among family medicine clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$1K
- Amarin Pharma, Inc.$881
- Novo Nordisk$782
- GSK$761
- Lilly USA, LLC$403
- plus $1K from 12 others
What the payments were for
- Food & beverage$6,48999%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 60 | $1,200 |
| AstraZeneca | 59 | $1,110 |
| Amarin Pharma, Inc. | 47 | $881 |
| Novo Nordisk | 44 | $782 |
| GSK | 63 | $761 |
| Lilly USA, LLC | 21 | $403 |
| Boehringer Ingelheim | 17 | $385 |
| Kowa Pharmaceuticals America, Inc. | 19 | $301 |
| Bayer | 14 | $288 |
| Novartis | 9 | $172 |
| Johnson & Johnson | 6 | $106 |
| Genentech USA, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Merck | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$6,542 in reported general payments places this provider in the 90th percentile of 376 family medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $71,879 |
| VascepaIcosapent Ethyl | 73 | $63,325 |
| RybelsusSemaglutide | 27 | $54,226 |
| OzempicSemaglutide | 23 | $40,739 |
| FarxigaDapagliflozin Propanediol | 32 | $39,581 |
| JanuviaSitagliptin Phosphate | 20 | $32,118 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $30,103 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $23,213 |
| ProliaDenosumab | 13 | $22,607 |
| Atorvastatin Calcium | 678 | $21,389 |
| EliquisApixaban | 19 | $16,886 |
| Olmesartan Medoxomil | 142 | $12,339 |
| Rosuvastatin Calcium | 204 | $10,305 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 95 | $10,078 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 60 | $6,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $385 | $95,09257 claims |
| Novo NordiskRybelsus, Ozempic | $782 | $94,96550 claims |
| AstraZenecaFarxiga | $1,110 | $39,58132 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $761 | $34,54536 claims |
| MerckJanuvia | $14 | $32,11820 claims |
| AmgenProlia | $1,200 | $22,60713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 376 family medicine providers in Hawaii.
Other family medicine in Honolulu
- Vicente RamoHonolulu$34K
- Choon YeoHonolulu$20K
- Gavino VinzonsHonolulu$15K
- Thuy-Linh NguyenHonolulu$9K
- Kelsey FinnHonolulu$5K
- Curtis Takemoto GentileHonolulu$4K
- Krishanna Takemoto-GentileHonolulu$4K
- Yoichi SomaHonolulu$4K
- Loan-Thy DangHonolulu$3K
- Ronnie OtienoHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.